2. Search Result
Search Result
Results for "

human IDO1

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

2

Natural
Products

1

Recombinant Proteins

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0353
    Curdione
    2 Publications Verification

    (+)-Curdione

    		 Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO) Cardiovascular Disease Neurological Disease Cancer
    Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression .
    Curdione
  • HY-RS06539
    IDO1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    IDO1 Human Pre-designed siRNA Set A contains three designed siRNAs for IDO1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IDO1 Human Pre-designed siRNA Set A
    IDO1 Human Pre-designed siRNA Set A
  • HY-173066
    NU227326

    		PROTACs Indoleamine 2,3-Dioxygenase (IDO) Cancer
    NU227326 is a blood-brain barrier penetrant IDO1 PROTAC degrader, with a DC50 of 4.5 nM in HiBiT degradation assays. NU227326 degrades IDO1 in U87 and GBM43 cells, with DC50 values of 7.1 nM and 11.8 nM, respectively (WB assays). NU227326 is applicable to research related to glioblastoma, prostate cancer, triple-negative breast cancer, pancreatic cancer, and ovarian cancer .
    NU227326
  • HY-156400
    IDO1-IN-23

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-23 (compound 41) is a potent human IDO1 inhibitor with an IC50 value of 13 μM .
    IDO1-IN-23
  • HY-184104
    IDO1/TDO-IN-17

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1/TDO-IN-17 is an IDO1/TDO inhibitor with human IDO1 IC50 ~280 μmol/L and human TDO IC50 204 μmol/L. IDO1/TDO-IN-17 binds to the heme-iron of IDO1. IDO1/TDO-IN-17 can be used for the research of cancer .
    IDO1/TDO-IN-17
  • HY-184135
    IDO/TDO-IN-2

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1/TDO-IN-2 is an IDO1/TDO inhibitor with both human IDO1 and human TDO pIC50 ≥5.50. IDO1/TDO-IN-2 can be used for the research of cancer .
    IDO/TDO-IN-2
  • HY-N0353R
    Curdione (Standard)

    (+)-Curdione (Standard)

    		 Reference Standards Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO) Others
    Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression .
    Curdione (Standard)
  • HY-148336A
    IDO1/TDO-IN-5

    		Indoleamine 2,3-Dioxygenase (IDO) Others
    IDO1/TDO-IN-5 is a potent dual IDO1/TDO inhibitor with IC50 valeus of 18 and 25 nM, respectively .
    IDO1/TDO-IN-5
  • HY-148336
    (E)-IDO1/TDO-IN-5

    		Drug Isomer Others
    (E)-IDO1/TDO-IN-5 is the E configuration of IDO1/TDO-IN-5 (HY-148336A). IDO1/TDO-IN-5 is a dual IDO1/TDO inhibitor with IC50 values of 0.018 and 0.025 μM, respectively .
    (E)-IDO1/TDO-IN-5
  • HY-184028
    IDO1-IN-37

    		Indoleamine 2,3-Dioxygenase (IDO) Inflammation/Immunology
    IDO1/TDO-IN-13 (Compound 40) is a selective, non-competitive IDO1 inhibitor with an IC50 of 0.106 μM against IDO1. IDO1/TDO-IN-13 is applicable to the research of inflammatory diseases .
    IDO1-IN-37
  • HY-184134
    IDO1/TDO-IN-16

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1/TDO-IN-16 (Fig.1 Compound 4) is a dual inhibitor of IDO1 and TDO. IDO1/TDO-IN-16 is applicable for cancer research .
    IDO1/TDO-IN-16
  • HY-184077
    IDO1-IN-35

    		Indoleamine 2,3-Dioxygenase (IDO) Infection
    IDO1-IN-35 (Compound 16) is an inhibitor of the IDO1 mutant IDO1 F164A. IDO1-IN-35 inhibits the IDO1-mediated conversion of L-tryptophan to N-formyl-L-kynurenine. IDO1-IN-35 can be used in studies of viral and bacterial infections .
    IDO1-IN-35
  • HY-W1011921
    TDO2-IN-3

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    TDO2-IN-3 (Compound 21) is a selective TDO2 inhibitor with an IC50 of 0.34 μM. TDO2-IN-3 can be used in cancer-related research .
    TDO2-IN-3
  • HY-184105
    IDO1-IN-36

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-36 (Compound 5a) is a selective, mixed-type IDO1 inhibitor with an IC50 of 0.72 μM against hIDO1. IDO1-IN-36 exhibits extremely low cytotoxicity in cancer cells. IDO1-IN-36 can be used for the research of breast cancer .
    IDO1-IN-36
  • HY-181947
    IDO1-IN-33

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-33 (Compound YC-16) is a IDO1 inhibitor (with an IC50 of 0.18 μM for IDO1 in HeLa cells). IDO1-IN-33 acts as an apo-IDO1 inhibitor by slowly and competitively displacing heme from mature holo-IDO1 and rapidly binding to the heme-binding site of immature apo-IDO1, without altering the expression level of IDO1. IDO1-IN-33 can be used for the research of hepatocellular carcinoma, non-small cell lung cancer, triple-negative breast cancer, and cervical cancer .
    IDO1-IN-33

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: